"Unequivocally Abnormal" vs "Usual" Signs and Symptoms for Proficient Diagnosis of Diabetic Polyneuropathy: Cl vs N Phys Trial - PubMed (original) (raw)
. 2012 Dec;69(12):1609-14.
doi: 10.1001/archneurol.2012.1481.
Carol J Overland, Phillip A Low, William J Litchy, Jenny L Davies, P James B Dyck, Rickey E Carter, L Joseph Melton, Henning Andersen, James W Albers, Charles F Bolton, John D England, Christopher J Klein, Gareth Llewelyn, Michelle L Mauermann, James W Russell, Dinesh Selvarajah, Wolfgang Singer, A Gordon Smith, Solomon Tesfaye, Adrian Vella
- PMID: 22986424
- PMCID: PMC3570730
- DOI: 10.1001/archneurol.2012.1481
"Unequivocally Abnormal" vs "Usual" Signs and Symptoms for Proficient Diagnosis of Diabetic Polyneuropathy: Cl vs N Phys Trial
Peter J Dyck et al. Arch Neurol. 2012 Dec.
Abstract
OBJECTIVE To repeat the Clinical vs Neurophysiology (Cl vs N Phys) trial using "unequivocally abnormal" signs and symptoms (Trial 2) compared with the earlier trial (Trial 1), which used "usual" signs and symptoms. DESIGN Standard and referenced nerve conduction abnormalities were used in both Trials 1 and 2 as the standard criterion indicative of diabetic sensorimotor polyneuropathy. Physician proficiency (accuracy among evaluators) was compared between Trials 1 and 2. SETTING Academic medical centers in Canada, Denmark, England, and the United States. PARTICIPANTS Thirteen expert neuromuscular physicians. One expert was replaced in Trial 2. RESULTS The marked overreporting, especially of signs, in Trial 1 was avoided in Trial 2. Reproducibility of diagnosis between days 1 and 2 was significantly (P = .005) better in Trial 2. The correlation of the following clinical scores with composite nerve conduction measures spanning the range of normality and abnormality was improved in Trial 2: pinprick sensation (P = .03), decreased reflexes (P = .06), touch-pressure sensation (P = .06), and the sum of symptoms (P = .06). CONCLUSIONS The simple pretrial decision to use unequivocally abnormal signs and symptoms-taking age, sex, and physical variables into account-in making clinical judgments for the diagnosis of diabetic sensorimotor polyneuropathy (Trial 2) improves physician proficiency compared with use of usual elicitation of signs and symptoms (Trial 1); both compare to confirmed nerve conduction abnormality.
Conflict of interest statement
Conflict of Interest Disclosures: None reported.
Figures
Figure 1
The clothing, masks, and dark glasses used to disguise the identity of patients (only 12 of the 24 patients are seen in the front row). The voices of patients were electronically altered. Patients did not speak unless physicians wore earphones. Some study personnel are also shown.
Figure 2
The frequency of at least 75% of expert physicians’ elicitation of signs, symptoms, and clinical diagnosis of diabetic sensorimotor polyneuropathy. Confirmed nerve conduction (NC) abnormality (calculated as the composite standard normal deviate score of 5 attributes of NC abnormality [Σ 5 NC nds ≤2.5th percentile]) is compared with results on days 1 and 2 of the Cl vs N Phys Trial 1 (A) and Trial 2 (a replication of Trial 1) (B). Percentages are calculated from 576 physician evaluations for 24 patients. Ellipses indicate not applicable. *Overreported clinical diagnoses were defined as the presence of clinical abnormalities but no NC abnormalities.
Similar articles
- Proficiency of nerve conduction using standard methods and reference values (Cl. NPhys Trial 4).
Litchy WJ, Albers JW, Wolfe J, Bolton CF, Walsh N, Klein CJ, Zafft AJ, Russell JW, Zwirlein M, Overland CJ, Davies JL, Carter RE, Dyck PJ; CI. Nphys Trial 4 Investigators. Litchy WJ, et al. Muscle Nerve. 2014 Dec;50(6):900-8. doi: 10.1002/mus.24243. Epub 2014 Oct 30. Muscle Nerve. 2014. PMID: 24644133 Free PMC article. - The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.
Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D; SYDNEY Trial Study Group. Ametov AS, et al. Diabetes Care. 2003 Mar;26(3):770-6. doi: 10.2337/diacare.26.3.770. Diabetes Care. 2003. PMID: 12610036 Clinical Trial. - Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy.
Dyck PJ, Karnes JL, Daube J, O'Brien P, Service FJ. Dyck PJ, et al. Brain. 1985 Dec;108 ( Pt 4):861-80. doi: 10.1093/brain/108.4.861. Brain. 1985. PMID: 4075076 - Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity.
Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, Feldman EL, Litchy WJ, O'Brien PC, Russell JW; Toronto Expert Panel on Diabetic Neuropathy. Dyck PJ, et al. Diabetes Metab Res Rev. 2011 Oct;27(7):620-8. doi: 10.1002/dmrr.1226. Diabetes Metab Res Rev. 2011. PMID: 21695763 Review. - Diagnostic tools for diabetic sensorimotor polyneuropathy.
Kles KA, Bril V. Kles KA, et al. Curr Diabetes Rev. 2006 Aug;2(3):353-61. doi: 10.2174/157339906777950598. Curr Diabetes Rev. 2006. PMID: 18220640 Review.
Cited by
- A trial of proficiency of nerve conduction: greater standardization still needed.
Dyck PJ, Albers JW, Wolfe J, Bolton CF, Walsh N, Klein CJ, Zafft AJ, Russell JW, Thomas K, Davies JL, Carter RE, Melton LJ 3rd, Litchy WJ; Clinical vs. Neurophysiology Trial 3 Investigators. Dyck PJ, et al. Muscle Nerve. 2013 Sep;48(3):369-74. doi: 10.1002/mus.23765. Epub 2013 Jul 17. Muscle Nerve. 2013. PMID: 23861198 Free PMC article. - Assessing decreased sensation and increased sensory phenomena in diabetic polyneuropathies.
Dyck PJ, Herrmann DN, Staff NP, Dyck PJ. Dyck PJ, et al. Diabetes. 2013 Nov;62(11):3677-86. doi: 10.2337/db13-0352. Diabetes. 2013. PMID: 24158999 Free PMC article. Review. - The sensitivity and specificity of the neurological examination in polyneuropathy patients with clinical and electrophysiological correlations.
Abraham A, Alabdali M, Alsulaiman A, Albulaihe H, Breiner A, Katzberg HD, Aljaafari D, Lovblom LE, Bril V. Abraham A, et al. PLoS One. 2017 Mar 1;12(3):e0171597. doi: 10.1371/journal.pone.0171597. eCollection 2017. PLoS One. 2017. PMID: 28249029 Free PMC article. Clinical Trial. - Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.
Adams D, Suhr OB, Dyck PJ, Litchy WJ, Leahy RG, Chen J, Gollob J, Coelho T. Adams D, et al. BMC Neurol. 2017 Sep 11;17(1):181. doi: 10.1186/s12883-017-0948-5. BMC Neurol. 2017. PMID: 28893208 Free PMC article. Clinical Trial. - Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Dyck PJ, Taylor BV, Davies JL, Mauermann ML, Litchy WJ, Klein CJ, Dyck PJ. Dyck PJ, et al. Muscle Nerve. 2015 Oct;52(4):488-97. doi: 10.1002/mus.24707. Epub 2015 Aug 13. Muscle Nerve. 2015. PMID: 25976871 Free PMC article. Review.
References
- Gilliatt RW. Clinical aspects of diabetic neuropathy. In: Cumings JN, Kremer M, editors. Biochemical Aspects of Neurological Disorders. Oxford, England: Blackwell; 1965. pp. 117–142.
- Pirart J. Diabetic neuropathy: a metabolic or a vascular disease? Diabetes. 1965;14:1–9. - PubMed
- Nilsson SV, Nilsson JE, Frostberg N, Emilsson T. The Kristianstad survey, II: studies in a representative adult diabetic population with special reference to comparison with an adequate control group. Acta Med Scand Suppl. 1967;469:1–42. - PubMed
- Franklin GM, Kahn LB, Baxter J, Marshall JA, Hamman RF. Sensory neuropathy in non–insulin-dependent diabetes mellitus: the San Luis Valley Diabetes Study. Am J Epidemiol. 1990;131(4):633–643. - PubMed
- England JD, Gronseth GS, Franklin G, et al. American Academy of Neurology; American Association of Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005;64(2):199–207. - PubMed